Home » Stocks » Zealand Pharma A/S

Zealand Pharma A/S (ZEAL)

Stock Price: $35.85 USD 1.09 (3.14%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.42B
Revenue (ttm) 5.82M
Net Income (ttm) 89.15M
Shares Out 39.67M
EPS (ttm) 3.00
PE Ratio 11.95
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $35.85
Previous Close $34.76
Change ($) 1.09
Change (%) 3.14%
Day's Open 35.40
Day's Range 35.29 - 35.88
Day's Volume 2,549
52-Week Range 18.75 - 44.60

More Stats

Market Cap 1.42B
Enterprise Value 1.24B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 39.67M
Float 28.34M
EPS (basic) n/a
EPS (diluted) 3.00
FCF / Share 3.20
Dividend n/a
Dividend Yield n/a
Earnings Yield 8.37%
FCF Yield 6.91%
Payout Ratio n/a
Shares Short 78,812
Short Ratio 12.98
Short % of Float n/a
Beta 1.13
PE Ratio 11.95
Forward PE n/a
P/FCF Ratio 14.46
PS Ratio 244.16
PB Ratio 8.07
Revenue 5.82M
Operating Income 100.06M
Net Income 89.15M
Free Cash Flow 98.32M
Net Cash 177.80M
Net Cash / Share 4.48
Gross Margin 100.00%
Operating Margin 1,717.86%
Profit Margin 1,530.60%
FCF Margin 1,687.95%
ROA -26.71%
ROE -54.23%
ROIC 294.20%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$43.07*
(20.14% upside)
Low
33.1
Current: 35.85
High
58.0
Target: 43.07
*Average 12-month USD price target from 7 stock analysts.

Financial Performance

Financial numbers in millions DKK.

Financial Overview

Year2018201720162015
Revenue37.98136231183
Revenue Growth-72.14%-40.95%26.45%-
Gross Profit37.98136231183
Operating Income652-249-119-85.74
Net Income581-275-157-118
Shares Outstanding30.7530.0930.09-
Earnings Per Share18.94-9.88-6.47-5.13
Operating Cash Flow-460-27940.90-225
Capital Expenditures1,101-7.11-2.60-4.04
Free Cash Flow641-28638.30-229
Cash & Equivalents1,159664323419
Total Debt-136332313
Net Cash / Debt1,159528-8.91106
Assets1,230721683628
Liabilities114207416383
Book Value1,116515267245
Numbers in millions DKK, except per-share numbers.

Company Profile

Company Details

Full Name Zealand Pharma A/S
Country Denmark
Employees 191
CEO Emmanuel Dulac

Stock Information

Ticker Symbol ZEAL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZEAL
IPO Date August 9, 2017

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.